Market: NASD |
Currency: USD
Address: 18105 SE Mill Plain Boulevard
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Show more
📈 Absci Corporation Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.82
-
Upside/Downside from Analyst Target:
226.99%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
25-50%
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
-0.19
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Absci Corporation
| Date | Reported EPS |
|---|
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 | -0.24 |
| 2025-05-13 | -0.21 |
| 2025-03-18 | -0.25 |
| 2024-11-12 | -0.24 |
| 2024-08-14 | -0.22 |
| 2024-05-14 | -0.22 |
| 2024-03-21 | -0.25 |
| 2023-11-14 | -0.24 |
| 2023-08-14 | -0.22 |
| 2023-05-15 | -0.26 |
| 2023-03-30 | -0.21 |
| 2022-11-09 | -0.3 |
| 2022-08-11 | -0.32 |
| 2022-05-11 | -0.33 |
| 2022-03-22 | -0.28 |
| 2021-11-09 | -0.33 |
| 2021-09-07 | -0.75 |
📰 Related News & Research
No related articles found for "absci corporation".
